Comprehensive Review on Phytoconstituents-based Nanomedicine for the Treatment of Atopic Dermatitis


Citar

Texto integral

Resumo

Atopic dermatitis (AD) is known as a chronic disease characterized by eczematous and pruritus skin lesions. The pathology behind atopic dermatitis etiology is loss of epidermal barrier, which prevents the production of protein filaggrin that can induce T-cell infiltration and inflammation. Treatment of AD is majorly based on limiting skin repair as well as reducing inflammation and itching. There are several remedies available for the treatment of AD, such as Janus kinase and calcineurin inhibitors, topical corticosteroids, and phosphodiesterase-4 inhibitors. The conventional formulations in the market have limited safety and efficacy. Hence, effective treatment of atopic dermatitis requires the development of novel, efficacious, reliable, and specific therapies. Recent research data have revealed that some naturally occurring medicinal plants have potential applications in the management of AD through different mechanisms. The nanotechnology-based therapeutics have gained a lot of attention in the last decade for the improvement in the activity of drugs having low absorption due to poor solubility, thus leading to lesser bioavailability. Therapies based on nanotechnology can be an effective way to overcome these obstacles. Due to their effective propensity to provide better drug diffusion and bioavailability as well as drug targeting potential at the desired site of action, these approaches may have decreased adverse drug effects, better penetration, and enhanced therapeutic efficacy. Hence, this review highlights the potential of phytoconstituents-based novel formulations for the treatment of atopic dermatitis. Furthermore, recent patents on therapeutic approaches to atopic dermatitis have also been briefly described.

Sobre autores

Mayuri Varshney

Institute of Pharmaceutical Research, GLA University

Email: info@benthamscience.net

Shiv Bahadur

Institute of Pharmaceutical Research, GLA University

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Mandlik, D.S.; Mandlik, S.K. Atopic dermatitis: New insight into the etiology, pathogenesis, diagnosis and novel treatment strategies. Immunopharmacol. Immunotoxicol., 2021, 43(2), 105-125. doi: 10.1080/08923973.2021.1889583 PMID: 33645388
  2. Ahmed, A.; Solman, L.; Williams, H.C. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: A critical appraisal. Br. J. Dermatol., 2018, 178(3), 659-662. doi: 10.1111/bjd.16046 PMID: 29205284
  3. Holm, J.G.; Thomsen, S.F. Omalizumab for atopic dermatitis: Evidence for and against its use. G. Ital. Dermatol. Venereol., 2019, 154(4), 480-487. doi: 10.23736/S0392-0488.19.06302-8 PMID: 30717578
  4. Yan, F.; Li, F.; Liu, J.; Ye, S.; Zhang, Y.; Jia, J.; Li, H.; Chen, D.; Mo, X. The formulae and biologically active ingredients of Chinese herbal medicines for the treatment of atopic dermatitis. Biomed. Pharmacother., 2020, 127, 110142. doi: 10.1016/j.biopha.2020.110142 PMID: 32330795
  5. Möbus, L.; Rodriguez, E.; Harder, I.; Schwarz, A.; Wehkamp, U.; Stölzl, D.; Boraczynski, N.; Gerdes, S.; Litman, T.; Kleinheinz, A.; Abraham, S.; Heratizadeh, A.; Handrick, C.; Haufe, E.; Schmitt, J.; Werfel, T.; Weidinger, S. Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitis. J. Allergy Clin. Immunol., 2021, 147(5), 1959-1965.e2. doi: 10.1016/j.jaci.2020.11.022 PMID: 33390269
  6. Palmer, C.N.A.; Irvine, A.D.; Terron-Kwiatkowski, A.; Zhao, Y.; Liao, H.; Lee, S.P.; Goudie, D.R.; Sandilands, A.; Campbell, L.E.; Smith, F.J.D.; O’Regan, G.M.; Watson, R.M.; Cecil, J.E.; Bale, S.J.; Compton, J.G.; DiGiovanna, J.J.; Fleckman, P.; Lewis-Jones, S.; Arseculeratne, G.; Sergeant, A.; Munro, C.S.; El Houate, B.; McElreavey, K.; Halkjaer, L.B.; Bisgaard, H.; Mukhopadhyay, S.; McLean, W.H.I. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet., 2006, 38(4), 441-446. doi: 10.1038/ng1767 PMID: 16550169
  7. Li, H.; Zhang, Z.; Zhang, H.; Guo, Y.; Yao, Z. Update on the pathogenesis and therapy of Atopic Dermatitis. Clin. Rev. Allergy Immunol., 2021, 61(3), 324-338. doi: 10.1007/s12016-021-08880-3 PMID: 34338977
  8. Sung, Y.Y.; Kim, H. Crocin ameliorates Atopic Dermatitis symptoms by down regulation of Th2 response via blocking of NF-κB/STAT6 signaling pathways in mice. Nutrients, 2018, 10(11), 1625. doi: 10.3390/nu10111625 PMID: 30400140
  9. Pribowo, A.; Girish, J.; Gustiananda, M.; Nandhira, R.G.; Hartrianti, P. Potential of Tamanu (Calophyllum inophyllum) Oil for Atopic Dermatitis Treatment. Evid. Based Complement. Alternat. Med., 2021, 2021, 1-9. doi: 10.1155/2021/6332867 PMID: 35069754
  10. Luger, T.; Amagai, M.; Dreno, B.; Dagnelie, M.A.; Liao, W.; Kabashima, K.; Schikowski, T.; Proksch, E.; Elias, P.M.; Simon, M.; Simpson, E.; Grinich, E.; Schmuth, M. Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents. J. Dermatol. Sci., 2021, 102(3), 142-157. doi: 10.1016/j.jdermsci.2021.04.007 PMID: 34116898
  11. Akan, A.; Dibek-Mısırlıoğlu, E.; Civelek, E.; Vezir, E.; Kocabaş, C.N. Diagnosis of atopic dermatitis in children: Comparison of the Hanifin-Rajka and the United Kingdom Working Party criteria. Allergol. Immunopathol. (Madr.), 2020, 48(2), 175-181. doi: 10.1016/j.aller.2019.07.008 PMID: 31611041
  12. Cheng, R.; Zhang, H.; Zong, W.; Tang, J.; Han, X.; Zhang, L.; Zhang, X.; Gu, H.; Shu, Y.; Peng, G.; Huang, L.; Liu, Q.; Gao, X.; Guo, Y.; Yao, Z. Development and validation of new diagnostic criteria for atopic dermatitis in children of China. J. Eur. Acad. Dermatol. Venereol., 2020, 34(3), 542-548. doi: 10.1111/jdv.15979 PMID: 31568595
  13. Manz, J.; Rodríguez, E.; ElSharawy, A.; Oesau, E.M.; Petersen, B.S.; Baurecht, H.; Mayr, G.; Weber, S.; Harder, J.; Reischl, E.; Schwarz, A.; Novak, N.; Franke, A.; Weidinger, S. Targeted resequencing and functional testing identifies low-frequency missense variants in the gene encoding GARP as significant contributors to Atopic Dermatitis risk. J. Invest. Dermatol., 2016, 136(12), 2380-2386. doi: 10.1016/j.jid.2016.07.009 PMID: 27448748
  14. Wu, S.; Pang, Y.; He, Y.; Zhang, X.; Peng, L.; Guo, J.; Zeng, J. A comprehensive review of natural products against atopic dermatitis: Flavonoids, alkaloids, terpenes, glycosides and other compounds. Biomed. Pharmacother., 2021, 140, 111741. doi: 10.1016/j.biopha.2021.111741 PMID: 34087696
  15. Kumar, S.; Pandey, A.K. Chemistry and biological activities of flavonoids: An overview. ScientificWorldJournal, 2013, 2013, 1-16. doi: 10.1155/2013/162750 PMID: 24470791
  16. Panche, A.N.; Diwan, A.D.; Chandra, S.R. Flavonoids: An overview. J. Nutr. Sci., 2016, 5, e47. doi: 10.1017/jns.2016.41 PMID: 28620474
  17. Lee, H.S.; Kim, E.N.; Jeong, G.S. Oral administration of Liquiritigenin confers protection from Atopic Dermatitis through the inhibition of T cell activation. Biomolecules, 2020, 10(5), 786. doi: 10.3390/biom10050786 PMID: 32438694
  18. Lee, D.; Park, J.; Choi, J.; Jang, H.; Seol, J. Anti-inflammatory effects of natural flavonoid diosmetin in IL-4 and LPS-induced macrophage activation and atopic dermatitis model. Int. Immunopharmacol., 2020, 89(Pt A), 107046. doi: 10.1016/j.intimp.2020.107046 PMID: 33045572
  19. Orita, K.; Hiramoto, K.; Kobayashi, H.; Ishii, M.; Sekiyama, A.; Inoue, M. Inducible nitric oxide synthase (iNOS) and α-melanocyte-stimulating hormones of iNOS origin play important roles in the allergic reactions of atopic dermatitis in mice. Exp. Dermatol., 2011, 20(11), 911-914. doi: 10.1111/j.1600-0625.2011.01360.x PMID: 21895774
  20. Park, S.; Bong, S.K.; Lee, J.W.; Park, N.J.; Choi, Y.; Kim, S.M.; Yang, M.H.; Kim, Y.K.; Kim, S.N. Diosmetin and its glycoside, diosmin, improve Atopic Dermatitis-like lesions in 2, 4-dinitrochlorobenzene-induced murine models. Biomol. Ther. (Seoul), 2020, 28(6), 542-548. doi: 10.4062/biomolther.2020.135 PMID: 32938818
  21. Hou, D.D.; Zhang, W.; Gao, Y.L.; Sun, Y.; Wang, H.X.; Qi, R.Q.; Chen, H.D.; Gao, X.H. Anti-inflammatory effects of quercetin in a mouse model of MC903-induced atopic dermatitis. Int. Immunopharmacol., 2019, 74, 105676. doi: 10.1016/j.intimp.2019.105676 PMID: 31181406
  22. Kim, T.H.; Kim, G.D.; Ahn, H.J.; Cho, J.J.; Park, Y.S.; Park, C.S. The inhibitory effect of naringenin on atopic dermatitis induced by DNFB in NC/Nga mice. Life Sci., 2013, 93(15), 516-524. doi: 10.1016/j.lfs.2013.07.027 PMID: 23933131
  23. Karuppagounder, V.; Arumugam, S.; Thandavarayan, R.A.; Sreedhar, R.; Giridharan, V.V.; Pitchaimani, V.; Afrin, R.; Harima, M.; Krishnamurthy, P.; Suzuki, K.; Nakamura, M.; Ueno, K.; Watanabe, K. Naringenin ameliorates skin inflammation and accelerates phenotypic reprogramming from M1 to M2 macrophage polarization in atopic dermatitis NC/Nga mouse model. Exp. Dermatol., 2016, 25(5), 404-407. doi: 10.1111/exd.12962 PMID: 26836240
  24. Moon, P.D.; Choi, I.H.; Kim, H.M. Naringenin suppresses the production of thymic stromal lymphopoietin through the blockade of RIP2 and caspase-1 signal cascade in mast cells. Eur. J. Pharmacol., 2011, 671(1-3), 128-132. doi: 10.1016/j.ejphar.2011.09.163 PMID: 21963452
  25. Nagula, R.L.; Wairkar, S. Cellulose microsponges based gel of naringenin for atopic dermatitis: Design, optimization, in vitro and in vivo investigation. Int. J. Biol. Macromol., 2020, 164, 717-725. doi: 10.1016/j.ijbiomac.2020.07.168 PMID: 32698069
  26. Yun, M.Y.; Yang, J.H.; Kim, D.K.; Cheong, K.J.; Song, H.H.; Kim, D.H.; Cheong, K.J.; Kim, Y.I.; Shin, S.C. Therapeutic effects of Baicalein on atopic dermatitis-like skin lesions of NC/Nga mice induced by dermatophagoides pteronyssinus. Int. Immunopharmacol., 2010, 10(9), 1142-1148. doi: 10.1016/j.intimp.2010.06.020 PMID: 20621172
  27. Huang, K.F.; Ma, K.H.; Liu, P.S.; Chen, B.W.; Chueh, S.H. Baicalein increases keratin 1 and 10 expression in HaCaT keratinocytes via TRPV4 receptor activation. Exp. Dermatol., 2016, 25(8), 623-629. doi: 10.1111/exd.13024 PMID: 27060689
  28. Nguyen, L.T.H.; Oh, T.W.; Nguyen, U.T.; Choi, M.J.; Yang, I.J.; Shin, H.M. A natural compound mixture containing Arctigenin, Hederagenin, and Baicalein alleviates Atopic Dermatitis in mice by regulating HPA Axis and immune activity. Evid. Based Complement. Alternat. Med., 2020, 2020, 1-13. doi: 10.1155/2020/1970349 PMID: 32714398
  29. Yang, L.; Stöckigt, J. Trends for diverse production strategies of plant medicinal alkaloids. Nat. Prod. Rep., 2010, 27(10), 1469-1479. doi: 10.1039/c005378c PMID: 20730220
  30. Aiello, A.; Fattorusso, E.; Imperatore, C.; Irace, C.; Luciano, P.; Menna, M.; Santamaria, R.; Vitalone, R. Zorrimidazolone, a bioactive alkaloid from the non-indigenous mediterranean stolidobranch Polyandrocarpa zorritensis. Mar. Drugs, 2011, 9(6), 1157-1165. doi: 10.3390/md9061157 PMID: 21747753
  31. Choi, D.W.; Jung, S.Y.; Shon, D.H.; Shin, H.S. Piperine Ameliorates Trimellitic anhydride-induced Atopic Dermatitis-like symptoms by suppressing Th2-mediated immune responses via inhibition of STAT6 phosphorylation. Molecules, 2020, 25(9), 2186. doi: 10.3390/molecules25092186 PMID: 32392825
  32. Chen, X.; Lin, J.; Liang, Q.; Chen, X.; Wu, Z. Pseudoephedrine alleviates atopic dermatitis-like inflammatory responses in vivo and in vitro. Life Sci., 2020, 258, 118139. doi: 10.1016/j.lfs.2020.118139 PMID: 32721463
  33. Wu, S.; Yu, D.; Liu, W.; Zhang, J.; Liu, X.; Wang, J.; Yu, M.; Li, Z.; Chen, Q.; Li, X.; Ye, X. Magnoflorine from Coptis chinese has the potential to treat DNCB-induced Atopic dermatits by inhibiting apoptosis of keratinocyte. Bioorg. Med. Chem., 2020, 28(2), 115093. doi: 10.1016/j.bmc.2019.115093 PMID: 31859028
  34. Lai, J.; Liu, Y.; Liu, C.; Qi, M.; Liu, R.; Zhu, X.; Zhou, Q.; Chen, Y.; Guo, A.; Hu, C. Indirubin inhibits LPS-induced inflammation via TLR4 abrogation mediated by the NF-kB and MAPK signaling pathways. Inflammation, 2017, 40(1), 1-12. doi: 10.1007/s10753-016-0447-7 PMID: 27718095
  35. Kim, M.H.; Choi, Y.Y.; Yang, G.; Cho, I.H.; Nam, D.; Yang, W.M. Indirubin, a purple 3,2- bisindole, inhibited allergic contact dermatitis via regulating T helper (Th)-mediated immune system in DNCB-induced model. J. Ethnopharmacol., 2013, 145(1), 214-219. doi: 10.1016/j.jep.2012.10.055 PMID: 23149289
  36. Han, N.R.; Moon, P.D.; Kim, H.M.; Jeong, H.J. Tryptanthrin ameliorates atopic dermatitis through down-regulation of TSLP. Arch. Biochem. Biophys., 2014, 542, 14-20. doi: 10.1016/j.abb.2013.11.010 PMID: 24295961
  37. Hortelano, S.; González-Cofrade, L.; Cuadrado, I.; de las Heras, B. Current status of terpenoids as inflammasome inhibitors. Biochem. Pharmacol., 2020, 172, 113739. doi: 10.1016/j.bcp.2019.113739 PMID: 31786260
  38. Park, J.H.; Yeo, I.J.; Han, J.H.; Suh, J.W.; Lee, H.P.; Hong, J.T. Anti-inflammatory effect of astaxanthin in phthalic anhydride-induced atopic dermatitis animal model. Exp. Dermatol., 2018, 27(4), 378-385. doi: 10.1111/exd.13437 PMID: 28887839
  39. Park, J.H.; Yeo, I.J.; Jang, J.S.; Kim, K.C.; Park, M.H.; Lee, H.P.; Han, S.B.; Hong, J.T. Combination effect of titrated extract of Centella asiatica and astaxanthin in a mouse model of phthalic anhydride-induced Atopic Dermatitis. Allergy Asthma Immunol. Res., 2019, 11(4), 548-559. doi: 10.4168/aair.2019.11.4.548 PMID: 31172723
  40. Yoshihisa, Y.; Andoh, T.; Matsunaga, K.; Rehman, M.U.; Maoka, T.; Shimizu, T. Efficacy of astaxanthin for the treatment of Atopic Dermatitis in a murine model. PLoS One, 2016, 11(3), e0152288. doi: 10.1371/journal.pone.0152288 PMID: 27023003
  41. Natsume, C.; Aoki, N.; Aoyama, T.; Senda, K.; Matsui, M.; Ikegami, A.; Tanaka, K.; Azuma, Y.T.; Fujita, T. Fucoxanthin ameliorates Atopic Dermatitis symptoms by regulating keratinocytes and regulatory innate lymphoid cells. Int. J. Mol. Sci., 2020, 21(6), 2180. doi: 10.3390/ijms21062180 PMID: 32235696
  42. Yang, H.; Jung, E.M.; Ahn, C.; Lee, G.S.; Lee, S.Y.; Kim, S.H.; Choi, I.G.; Park, M.J.; Lee, S.S.; Choi, D.H.; Jeung, E.B. Elemol from Chamaecyparis obtusa ameliorates 2,4-dinitrochlorobenzene-induced atopic dermatitis. Int. J. Mol. Med., 2015, 36(2), 463-472. doi: 10.3892/ijmm.2015.2228 PMID: 26035417
  43. Lin, G.; Gao, S.; Cheng, J.; Li, Y.; Shan, L.; Hu, Z. 1 β -Hydroxyalantolactone, a sesquiterpene lactone from Inula japonica, attenuates atopic dermatitis-like skin lesions induced by 2,4-dinitrochlorobenzene in the mouse. Pharm. Biol., 2016, 54(3), 516-522. doi: 10.3109/13880209.2015.1050745 PMID: 26017682
  44. Choi, J.H.; Jin, S.W.; Han, E.H.; Park, B.H.; Kim, H.G.; Khanal, T.; Hwang, Y.P.; Do, M.T.; Lee, H.S.; Chung, Y.C.; Kim, H.S.; Jeong, T.C.; Jeong, H.G. Platycodon grandiflorum root-derived saponins attenuate atopic dermatitis-like skin lesions via suppression of NF-κB and STAT1 and activation of Nrf2/ARE-mediated heme oxygenase-1. Phytomedicine, 2014, 21(8-9), 1053-1061. doi: 10.1016/j.phymed.2014.04.011 PMID: 24854572
  45. Bartnik, M.; Facey, P.C. Glycosides.Pharmacognosy; Academic Press: Massachusetts, 2017, pp. 101-161. doi: 10.1016/B978-0-12-802104-0.00008-1
  46. Ahn, J.Y.; Choi, S.E.; Jeong, M.S.; Park, K.H.; Moon, N.J.; Joo, S.S.; Lee, C.S.; Choi, Y.W.; Li, K.; Lee, M.K.; Lee, M.W.; Seo, S.J. Effect of taxifolin glycoside on atopic dermatitis-like skin lesions in NC/Nga mice. Phytother. Res., 2010, 24(7), 1071-1077. doi: 10.1002/ptr.3084 PMID: 20041431
  47. Kim, J.Y.; Lee, O.S.; Ha, S.; Kim, J.H.; Park, G.; Kim, J.K.; Oh, C.H. In vivo assessment of the effect of taxifolin glycoside on atopic dermatitis-like skin lesions using biomedical tools in NC/Nga mice. Clin. Exp. Dermatol., 2015, 40(5), 547-555. doi: 10.1111/ced.12522 PMID: 25475067
  48. Kang, M.J.; Eum, J.Y.; Park, S.H.; Kang, M.H.; Park, K.H.; Choi, S.E.; Lee, M.W.; Kang, K.H.; Oh, C.H.; Choi, Y.W. Pep-1 peptide-conjugated elastic liposomal formulation of taxifolin glycoside for the treatment of atopic dermatitis in NC/Nga mice. Int. J. Pharm., 2010, 402(1-2), 198-204. doi: 10.1016/j.ijpharm.2010.09.030 PMID: 20888893
  49. Jegal, J.; Park, N.J.; Jo, B.G.; Bong, S.K.; Jegal, H.; Yang, M.; Kim, S.N. Anti-Atopic properties of gracillin isolated from Dioscorea quinqueloba on 2, 4-dinitrochlorobenzene-induced skin lesions in mice. Nutrients, 2018, 10(9), 1205. doi: 10.3390/nu10091205 PMID: 30200442
  50. Ingawale, D.K.; Mandlik, S.K.; Patel, S.S. Anti-inflammatory potential of hecogenin on atopic dermatitis and airway hyper-responsiveness by regulation of pro-inflammatory cytokines. Immunopharmacol. Immunotoxicol., 2019, 41(2), 327-336. doi: 10.1080/08923973.2019.1608445 PMID: 31039648
  51. Georgiev, M.; Pastore, S.; Lulli, D.; Alipieva, K.; Kostyuk, V.; Potapovich, A.; Panetta, M.; Korkina, L. Verbascum xanthophoeniceum-derived phenylethanoid glycosides are potent inhibitors of inflammatory chemokines in dormant and interferon-gamma-stimulated human keratinocytes. J. Ethnopharmacol., 2012, 144(3), 754-760. doi: 10.1016/j.jep.2012.10.035 PMID: 23117092
  52. Li, Y.; Yu, H.; Jin, Y.; Li, M.; Qu, C. Verbascoside alleviates Atopic Dermatitis-like symptoms in mice via its potent anti-inflammatory effect. Int. Arch. Allergy Immunol., 2018, 175(4), 220-230. doi: 10.1159/000486958 PMID: 29587260
  53. Karuppagounder, V.; Arumugam, S.; Thandavarayan, R.A.; Pitchaimani, V.; Sreedhar, R.; Afrin, R.; Harima, M.; Suzuki, H.; Nomoto, M.; Miyashita, S.; Suzuki, K.; Nakamura, M.; Ueno, K.; Watanabe, K. Tannic acid modulates NFκB signaling pathway and skin inflammation in NC/Nga mice through PPARγ expression. Cytokine, 2015, 76(2), 206-213. doi: 10.1016/j.cyto.2015.05.016 PMID: 26049169
  54. Noh, S.U.; Cho, E.A.; Kim, H.O.; Park, Y.M. Epigallocatechin-3-gallate improves Dermatophagoides pteronissinus extract-induced atopic dermatitis-like skin lesions in NC/Nga mice by suppressing macrophage migration inhibitory factor. Int. Immunopharmacol., 2008, 8(9), 1172-1182. doi: 10.1016/j.intimp.2008.04.002 PMID: 18602062
  55. Shimizu, T.; Abe, R.; Ohkawara, A.; Mizue, Y.; Nishihira, J. Macrophage migration inhibitory factor is an essential immunoregulatory cytokine in atopic dermatitis. Biochem. Biophys. Res. Commun., 1997, 240(1), 173-178. doi: 10.1006/bbrc.1997.7633 PMID: 9367905
  56. An, E.J.; Kim, Y.; Lee, S.H.; Choi, S.H.; Chung, W.S.; Jang, H.J. Ophiopogonin D ameliorates DNCB-induced atopic dermatitis-like lesions in BALB/c mice and TNF-α- inflamed HaCaT cell. Biochem. Biophys. Res. Commun., 2020, 522(1), 40-46. doi: 10.1016/j.bbrc.2019.10.190 PMID: 31735336
  57. Shenefelt, PD Herbal treatment for dermatologic disorders. Herbal Medicine: Biomolecular and Clinical Aspects, 2nd ed.; National Library of Medicine: Rockville Pike, 2011. doi: 10.1201/b10787-19
  58. Hoffmann, J.; Gendrisch, F.; Schempp, C.M.; Wölfle, U. New herbal biomedicines for the topical treatment of dermatological disorders. Biomedicines, 2020, 8(2), 27. doi: 10.3390/biomedicines8020027 PMID: 32046246
  59. Bae, M.J.; Lim, S.; Lee, D.S.; Ko, K.R.; Lee, W.; Kim, S. Water soluble extracts from Actinidia arguta, PG102, attenuates house dust mite-induced murine atopic dermatitis by inhibiting the mTOR pathway with Treg generation. J. Ethnopharmacol., 2016, 193, 96-106. doi: 10.1016/j.jep.2016.08.004 PMID: 27496579
  60. Han, H.M.; Kim, S.J.; Kim, J.S.; Kim, B.H.; Lee, H.W.; Lee, Y.T.; Kang, K.H. Ameliorative effects of Artemisia argyi Folium extract on 2,4-dinitrochlorobenzene-induced atopic dermatitis-like lesions in BALB/c mice. Mol. Med. Rep., 2016, 14(4), 3206-3214. doi: 10.3892/mmr.2016.5657 PMID: 27571702
  61. Ryu, K.J.; Yoou, M.S.; Seo, Y.; Yoon, K.W.; Kim, H.M.; Jeong, H.J. Therapeutic effects of Artemisia scoparia Waldst. et Kitaib in a murine model of atopic dermatitis. Clin. Exp. Dermatol., 2018, 43(7), 798-805. doi: 10.1111/ced.13565 PMID: 29740850
  62. Ku, J.M.; Hong, S.H.; Kim, H.I.; Seo, H.S.; Shin, Y.C.; Ko, S.G. Effects of Angelicae dahuricae Radix on 2, 4-dinitrochlorobenzene-induced Atopic Dermatitis-like skin lesions in mice model. BMC Complement. Altern. Med., 2017, 17(1), 98. doi: 10.1186/s12906-017-1584-8 PMID: 28173791
  63. Qi, X.F.; Kim, D.H.; Yoon, Y.S.; Li, J.H.; Jin, D.; Deung, Y.K.; Lee, K.J. Effects of Bambusae caulis in Liquamen on the development of atopic dermatitis-like skin lesions in hairless mice. J. Ethnopharmacol., 2009, 123(2), 195-200. doi: 10.1016/j.jep.2009.03.020 PMID: 19429362
  64. Kim, E.C.; Lee, H.S.; Kim, S.K.; Choi, M.S.; Lee, S.; Han, J.B.; An, H.J.; Um, J.Y.; Kim, H.M.; Lee, N.Y.; Bae, H.; Min, B.I. The bark of Betula platyphylla var. japonica inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice. J. Ethnopharmacol., 2008, 116(2), 270-278. doi: 10.1016/j.jep.2007.11.042 PMID: 18191513
  65. Lee, J.K.; Ha, H.; Lee, H.Y.; Park, S.J.; Jeong, S.; Choi, Y.J.; Shin, H.K. Inhibitory effects of heartwood extracts of Broussonetia kazinoki Sieb on the development of atopic dermatitis in NC/Nga mice. Biosci. Biotechnol. Biochem., 2010, 74(9), 1802-1806. doi: 10.1271/bbb.100138 PMID: 20834170
  66. Hong, S.; Ku, J.; Kim, H.; Lee, S.; Lim, Y.; Seo, H.; Shin, Y.; Ko, S.G. Oral administration of Cervus nippon mantchuricus extract suppresses 2,4-dinitrochlorobenzene-induced atopic dermatitis in BALB/c mice and inflammatory effects in mast cells. Int. J. Mol. Med., 2018, 42(5), 2961-2971. doi: 10.3892/ijmm.2018.3856 PMID: 30226556
  67. Choi, Y.Y.; Kim, M.H.; Lee, H.; Ahn, K.S.; Um, J.Y.; Lee, S.; Kim, J.; Yang, W.M. Cynanchum atratum inhibits the development of atopic dermatitis in 2,4-dinitrochlorobenzene-induced mice. Biomed. Pharmacother., 2017, 90, 321-327. doi: 10.1016/j.biopha.2017.03.065 PMID: 28365521
  68. Sung, Y.Y.; Yoon, T.; Jang, J.Y.; Park, S.J.; Jeong, G.H.; Kim, H.K. Inhibitory effects of Cinnamomum cassia extract on atopic dermatitis-like skin lesions induced by mite antigen in NC/Nga mice. J. Ethnopharmacol., 2011, 133(2), 621-628. doi: 10.1016/j.jep.2010.10.043 PMID: 21035532
  69. Kim, H.; Yang, B.; Lyu, J.H.; Kim, S.; Park, Y.C.; Kim, K. Dictamnus dasycarpus Turcz., root bark alleviates oxazolone-induced atopy-like dermatitis in mice. Pharmacogn. Mag., 2019, 15(61), 219. doi: 10.4103/pm.pm_110_18
  70. Sung, Y.Y.; Yoon, T.; Jang, S.; Kim, H.K. Forsythia suspensa suppresses house dust mite extract-induced atopic dermatitis in NC/Nga mice. PLoS One, 2016, 11(12), e0167687. doi: 10.1371/journal.pone.0167687 PMID: 27936051
  71. Sung, Y.Y.; Lee, A.Y.; Kim, H.K. The Gardenia jasminoides extract and its constituent, geniposide, elicit anti-allergic effects on atopic dermatitis by inhibiting histamine in vitro and in vivo. J. Ethnopharmacol., 2014, 156, 33-40. doi: 10.1016/j.jep.2014.07.060 PMID: 25153023
  72. Kim, T.; Park, K.; Jung, H.S.; Kong, W.S.; Jeon, D.; Lee, S.H. Evaluation of anti-atopic dermatitis activity of Hypsizigus marmoreus extract. Phytother. Res., 2014, 28(10), 1539-1546. doi: 10.1002/ptr.5164 PMID: 24839932
  73. Lim, H.S.; Ha, H.; Lee, H.; Lee, J.K.; Lee, M.Y.; Shin, H.K. Morus alba L. suppresses the development of atopic dermatitis induced by the house dust mite in NC/Nga mice. BMC Complement. Altern. Med., 2014, 14(1), 139. doi: 10.1186/1472-6882-14-139 PMID: 24755250
  74. Lee, S-H.; Nam, D.Y.; Seo, M.S.; Lee, S.H. Alleviation of atopic dermatitis-related symptoms by Perilla frutescens Britton. Int. J. Mol. Med., 2011, 28(5), 733-737. doi: 10.3892/ijmm.2011.763 PMID: 21811759
  75. Jin, J.H.; Ngoc, T.M.; Bae, K.; Kim, Y.S.; Kim, H.P. Inhibition of experimental atopic dermatitis by rhubarb (rhizomes of Rheum tanguticum) and 5-lipoxygenase inhibition of its major constituent, emodin. Phytother. Res., 2011, 25(5), 755-759. doi: 10.1002/ptr.3480 PMID: 21442678
  76. Kang, Y.H.; Shin, H.M. Inhibitory effects of Schizandra chinensis extract on atopic dermatitis in NC/Nga mice. Immunopharmacol. Immunotoxicol., 2012, 34(2), 292-298. doi: 10.3109/08923973.2011.602689 PMID: 21854164
  77. Kim, J.; Lee, I.; Park, S.; Choue, R. Effects of Scutellariae radix and Aloe vera gel extracts on immunoglobulin E and cytokine levels in atopic dermatitis NC/Nga mice. J. Ethnopharmacol., 2010, 132(2), 529-532. doi: 10.1016/j.jep.2010.08.049 PMID: 20817082
  78. Kang, S.Y.; Jung, H.W.; Nam, J.H.; Kim, W.K.; Kang, J.S.; Kim, Y.H.; Cho, C.W.; Cho, C.W.; Park, Y.K.; Bae, H.S. Effects of the fruit extract of Tribulus terrestris on skin inflammation in mice with oxazolone-induced atopic dermatitis through regulation of calcium channels, orai-1 and TRPV3, and mast cell activation. Evid. Based Complement. Alternat. Med., 2017, 2017, 1-12. doi: 10.1155/2017/8312946 PMID: 29348776
  79. Saeedi, M.; Morteza-Semnani, K.; Ghoreishi, M-R. The treatment of atopic dermatitis with licorice gel. J. Dermatolog. Treat., 2003, 14(3), 153-157. doi: 10.1080/09546630310014369 PMID: 14522625
  80. Sirikudta, W.; Kulthanan, K.; Varothai, S.; Nuchkull, P. Moisturizers for patients with atopic dermatitis: An overview. J. Allergy Ther., 2013, 4(4), 1-6. doi: 10.4172/2155-6121.1000143
  81. Gupta, V.; Sanyogita, K.; Manigauha, A. Novel Formulation of Aloe Vera and Quercetin in the Management of Dermal Disease: Eczema. J. Pharm. Drug Res., 2021, 4(2), 480-487. doi: 10.13140/RG.2.2.21014.27207
  82. Ramos Campos, E.V.; Proença, P.L.D.F.; Doretto-Silva, L.; Andrade-Oliveira, V.; Fraceto, L.F.; de Araujo, D.R. Trends in nanoformulations for atopic dermatitis treatment. Expert Opin. Drug Deliv., 2020, 17(11), 1615-1630. doi: 10.1080/17425247.2020.1813107 PMID: 32816566
  83. Mezei, M.; Gulasekharam, V. Liposomes - a selective drug delivery system for the topical route of administration I. Lotion dosage form. Life Sci., 1980, 26(18), 1473-1477. doi: 10.1016/0024-3205(80)90268-4 PMID: 6893068
  84. Krishnan, V.; Mitragotri, S. Nanoparticles for topical drug delivery: Potential for skin cancer treatment. Adv. Drug Deliv. Rev., 2020, 153, 87-108. doi: 10.1016/j.addr.2020.05.011 PMID: 32497707
  85. Raza, K.; Shareef, M.A.; Singal, P.; Sharma, G.; Negi, P.; Katare, O.P. Lipid-based capsaicin-loaded nano-colloidal biocompatible topical carriers with enhanced analgesic potential and decreased dermal irritation. J. Liposome Res., 2014, 24(4), 290-296. doi: 10.3109/08982104.2014.911314 PMID: 24766639
  86. Abdel-Mottaleb, M.M.A.; Moulari, B.; Beduneau, A.; Pellequer, Y.; Lamprecht, A. Nanoparticles enhance therapeutic outcome in inflamed skin therapy. Eur. J. Pharm. Biopharm., 2012, 82(1), 151-157. doi: 10.1016/j.ejpb.2012.06.006 PMID: 22728016
  87. Badihi, A.; Frušić-Zlotkin, M.; Soroka, Y.; Benhamron, S.; Tzur, T.; Nassar, T.; Benita, S. Topical nano-encapsulated cyclosporine formulation for atopic dermatitis treatment. Nanomedicine, 2020, 24, 102140. doi: 10.1016/j.nano.2019.102140 PMID: 31830614
  88. Baspinar, Y.; Keck, C.M.; Borchert, H.H. Development of a positively charged prednicarbate nanoemulsion. Int. J. Pharm., 2010, 383(1-2), 201-208. doi: 10.1016/j.ijpharm.2009.09.002 PMID: 19747968
  89. Bernardi, D.S.; Pereira, T.A.; Maciel, N.R.; Bortoloto, J.; Viera, G.S.; Oliveira, G.C.; Rocha-Filho, P.A. Formation and stability of oil-in-water nanoemulsions containing rice bran oil: in vitro and in vivo assessments. J. Nanobiotechnology, 2011, 9(1), 44. doi: 10.1186/1477-3155-9-44 PMID: 21952107
  90. Espinoza, L.C.; Silva-Abreu, M.; Calpena, A.C.; Rodríguez-Lagunas, M.J.; Fábrega, M.J.; Garduño-Ramírez, M.L.; Clares, B. Nanoemulsion strategy of pioglitazone for the treatment of skin inflammatory diseases. Nanomedicine, 2019, 19, 115-125. doi: 10.1016/j.nano.2019.03.017 PMID: 31004811
  91. Hemrajani, C.; Negi, P.; Parashar, A.; Gupta, G.; Jha, N.K.; Singh, S.K.; Chellappan, D.K.; Dua, K. Overcoming drug delivery barriers and challenges in topical therapy of atopic dermatitis: A nanotechnological perspective. Biomed. Pharmacother., 2022, 147, 112633. doi: 10.1016/j.biopha.2022.112633 PMID: 35030434
  92. Paiva-Santos, A.C.; Silva, A.L.; Guerra, C.; Peixoto, D.; Pereira-Silva, M.; Zeinali, M.; Mascarenhas-Melo, F.; Castro, R.; Veiga, F. Ethosomes as nanocarriers for the development of skin delivery formulations. Pharm. Res., 2021, 38(6), 947-970. doi: 10.1007/s11095-021-03053-5 PMID: 34036520
  93. Kang, M.J.; Eum, J.Y.; Jeong, M.S.; Choi, S.E.; Park, S.H.; Cho, H.I.; Cho, C.S.; Seo, S.J.; Lee, M.W.; Choi, Y.W. Facilitated skin permeation of oregonin by elastic liposomal formulations and suppression of atopic dermatitis in NC/Nga mice. Biol. Pharm. Bull., 2010, 33(1), 100-106. doi: 10.1248/bpb.33.100 PMID: 20045944
  94. Choi, Y.; Kang; Eum; Jeong; Park; Moon; Kang; Choi, S.E.; Lee, M.W.; Lee, D.I.; Bang, H.; Lee, C.S.; Joo, S.S.; Li, K.; Lee, M.K.; Seo, S.J.; Kim, Tat peptide-admixed elastic liposomal formulation of hirsutenone for the treatment of atopic dermatitis in Nc/Nga mice. Int. J. Nanomedicine, 2011, 6, 2459-2467. doi: 10.2147/IJN.S24350 PMID: 22072881
  95. Priprem, A.; Janpim, K.; Nualkaew, S.; Mahakunakorn, P. Topical niosome gel of Zingiber cassumunar Roxb. extract for anti-inflammatory activity enhanced skin permeation and stability of compound D. AAPS PharmSciTech, 2016, 17(3), 631-639. doi: 10.1208/s12249-015-0376-z PMID: 26292930
  96. Suryawanshi, J.S. Phytosome: An emerging trend in herbal drug treatment. J Med Genet Genomics., 2011, 3(6), 109-114.
  97. Vickers, N.J. Animal communication: When i’m calling you, will you answer too? Curr. Biol., 2017, 27(14), R713-R715. doi: 10.1016/j.cub.2017.05.064 PMID: 28743020
  98. Neelam, K.; Vijay, S.; Lalit, S. Various techniques for the modification of starch and the applications of its derivatives. Int Res J Pharm., 2012, 3(5), 25-31.
  99. Ju Ho, P.; Jun Sung, J.; Ki Cheon, K.; Jin Tae, H. Anti-inflammatory effect of Centella asiatica phytosome in a mouse model of phthalic anhydride-induced atopic dermatitis. Phytomedicine, 2018, 43, 110-119. doi: 10.1016/j.phymed.2018.04.013 PMID: 29747743
  100. Togni, S.; Riva, A.; Maramaldi, G.; Cesarone, M.R.; Belcaro, G. Oral curcumin (Meriva®) reduces symptoms and recurrence rates in subjects with atopic dermatitis. Esperienze Dermatol., 2020, 21(2-4), 42-46. doi: 10.23736/S1128-9155.19.00486-2
  101. Kumari, S.; Goyal, A.; Sönmez Gürer, E.; Algın Yapar, E.; Garg, M.; Sood, M.; Sindhu, R.K. Bioactive Loaded Novel Nano-Formulations for Targeted Drug Delivery and Their Therapeutic Potential. Pharmaceutics, 2022, 14(5), 1091. doi: 10.3390/pharmaceutics14051091 PMID: 35631677
  102. Sahu, S.; Saraf, S.; Kaur, C.D.; Saraf, S. Biocompatible nanoparticles for sustained topical delivery of anticancer phytoconstituent quercetin. Pak. J. Biol. Sci., 2013, 16(13), 601-609. doi: 10.3923/pjbs.2013.601.609 PMID: 24505982
  103. Wang, Y.; Cao, S.; Yu, K.; Yang, F.; Yu, X.; Zhai, Y.; Wu, C.; Xu, Y. Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: Simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects. Int. J. Nanomedicine, 2019, 14, 5849-5863. doi: 10.2147/IJN.S212260 PMID: 31440050
  104. Marto, J.; Ruivo, E.; Lucas, S.D.; Gonçalves, L.M.; Simões, S.; Gouveia, L.F.; Felix, R.; Moreira, R.; Ribeiro, H.M.; Almeida, A.J. Starch nanocapsules containing a novel neutrophil elastase inhibitor with improved pharmaceutical performance. Eur. J. Pharm. Biopharm., 2018, 127, 1-11. doi: 10.1016/j.ejpb.2018.01.011 PMID: 29409864
  105. Mroginski Weber, D.; Voss, G.T.; de Oliveira, R.L.; da Fonseca, C.A.R.; Paltian, J.; Rodrigues, K.C.; Rodrigues Ianiski, F.; Vaucher, R.A.; Luchese, C.; Antunes Wilhelm, E. Topic application of meloxicam-loaded polymeric nanocapsules as a technological alternative for treatment of the atopic dermatitis in mice. J. Appl. Biomed., 2018, 16(4), 337-343. doi: 10.1016/j.jab.2018.03.003
  106. Parekh, K.; Mehta, T.A.; Dhas, N.; Kumar, P.; Popat, A. Emerging nanomedicines for the treatment of atopic dermatitis. AAPS PharmSciTech, 2021, 22(2), 55. doi: 10.1208/s12249-021-01920-3 PMID: 33486609
  107. Kwon, T.K.; Kim, J.C. In vitro skin permeation and anti-atopic efficacy of lipid nanocarriers containing water soluble extracts of Houttuynia cordata. Drug Dev. Ind. Pharm., 2014, 40(10), 1350-1357. doi: 10.3109/03639045.2013.819883 PMID: 23886304
  108. Fang, Ma Traditional Chinese medicine for treating phytophotodermatitis. CN103830620A, 2014.
  109. Junior, Dante Alario; Pereira, Jose Roberto Da Costa Topical pharmaceutical composition, method for producing the topical pharmaceutical composition, use of the topical pharmaceutical composition and method for the topical treatment of psoriasis, atopic dermatitis or chronic eczema. WO2013155584A1, 2013.
  110. Eun-kyung, Ahn; Seong-soo, Hong Composition for Improving Atopy Dermatitis Using an Extract of Scirpus karuizawensis. KR20220076983A, 2022.
  111. Kang, Jae-Shin; Le, Jaeho; Yoo, Eunhwa; Cry, Marsfal; Chang, Kimsun Composition for Improving Atopy Dermatitis Using an Extract of Careya arborea. KR102087651B1, 2020.
  112. Jeon, Minkyu; Shin-young, Park; Kim, Yunyeon Composition for prevention and treatment of atopic dermatitis comprising bifidobacterium animal's subsp. lactis lm1017 derived from Korean infants. KR102136346B1, 2020.
  113. André, Philippe; Shantara, Laurent; Lin, Ink Treatment of atopic dermatitis with extracts of indigo naturalis or indigo-producing plants. JP6803849B2, 2020.
  114. Abdulrahman, Muna; Abdulrahman, Mohamed Formulations for Cosmetic and Dermatological Applications. US20190160134A1, 2019.
  115. Jing, Ruan Composition capable of relieving eczema skin condition, and preparation method therefor. WO2021082298A1, 2021.
  116. Yong-won, Song Composition for treating atopic dermatitis using natural materials. WO2012036446A2, 2012.
  117. Ga-young, Noh; Jae-young, Noh Therapeutic effects cream for anti-atopic. KR101313660B1, 2013.
  118. Oucrea, Christian Composition comprising dihydroquercetin for use in a method of treating an action associated with a skin inflammatory disorder. JP2017505806A, 2017.
  119. Ahn, Taekwon; Park, Jungmi; Tae-soo, Jang; Choi, Heejeong Pharmaceutical Compositions Comprising Aralia cordata var. continent- ails Composite oil Having Anti-atopy. KR20190031985A, 2020.
  120. Seong-yul, Park Composition for treating atopic dermatitis comprising Patrinia scabiosaefolia and Dioscorea opposita extracts. KR20200080497A, 2020.
  121. Ji-hwan, Joo; Kim, Donghee; Boo-yong, Shim A composite for improving atopic dermatitis treatment using apples. KR101923343B1, 2018.
  122. Lee, Hwanmyeong; Kim, Doyoon; Hwang, Daeil; Soo-min, Park; Kim, Miyeon; Lee, Sehee Composition for treating atopic dermatitis or reinforcing skin barrier containing chrysanthemum bore-ale makino essential oil or 1-iodohexadecan. KR20190007184A, 2019.
  123. Jeong, Hyeoksang; Son, Youngjoo; Park, Jaeho; Eun-young, Kim Composition comprising Fritillariae Thunbergii Bulbs extract for preventing or treating atopic dermatitis. KR102209969B1, 2021.
  124. Jeong, Hyeoksang; Son, Youngjoo; Jwa-jin, Kim; Park, Jaeho; Eun-young, Kim; Ga-yul, Min A composition for preventing or terating atopic dermatitis comprising lycopi herba extract as an active ingredient. KR102144566B1, 2020.
  125. Dae-hyun, Ham; Hye-jeong, Lee; Bong-joon, Seo Composition comprising Polygala tenuifolia extract for preventing or treating atopic dermatitis. KR20150086982A, 2015.
  126. Jang, Seonil Composition for preventing, improving or treating atopic dermatitis comprising extract mixture of Diospyros lotus leaf and grape fruit stem as effective component. KR101934794B1, 2019.
  127. Yang, Jaekyung; Kim, Rumi; Hasiyoung, Jongcheol Kim; Kim, Taeheung; Ji-young, Jeong; Seung-cheol, Park Composition for improving atopic dermatitis comprising extract of steamed green tea. KR101330411B1, 2013.
  128. Cai, Ruikang; Yuan, Hailong; Yan, Wu; Shen, Chengying; Rong, Xu; Si, Zhang Traditional Chinese medicine composition and granules for treating atopic dermatitis and preparation method. CN105998164A, 2020.
  129. Chen, Dacan Chinese medicinal composition for treating atopic dermatitis and preparation method thereof. CN103393981A, 2015.
  130. Fever, Margin; Tae-ho, Jeong Composition for preventing or treating atopic dermatitis including galenical extract or lactobacillus fermentation thereof. WO2012043920A1, 2012.
  131. Hyun-sook, Kim Atopic dermatitis remedy and method for producing the same. KR101977908B1, 2019.
  132. Hwang, Incheol Manufacturing method of composition comprising natural extracts for treating atopic dermatitis. KR101605623B1, 2016.
  133. Ahuja, A.; Gupta, J.; Gupta, R. Miracles of herbal phytomedicines in treatment of skin disorders: Natural healthcare perspective. Infect. Disord. Drug Targets, 2021, 21(3), 328-338. doi: 10.2174/1871526520666200622142710 PMID: 32568024
  134. Garg, A.; Chaturvedi, S. A Comprehensive Review on Chrysin: Emphasis on Molecular Targets, Pharmacological Actions and Bio-pharmaceutical Aspects. Curr. Drug Targets, 2022, 23(4), 420-436. doi: 10.2174/1389450122666210824141044 PMID: 34431464
  135. Cláudia Paiva-Santos, A.; Gama, M.; Peixoto, D.; Sousa-Oliveira, I.; Ferreira-Faria, I.; Zeinali, M.; Abbaspour-Ravasjani, S.; Mascarenhas-Melo, F.; Hamishehkar, H.; Veiga, F. Nanocarrier-based dermopharmaceutical formulations for the topical management of atopic dermatitis. Int. J. Pharm., 2022, 618, 121656. doi: 10.1016/j.ijpharm.2022.121656 PMID: 35278601
  136. Chaturvedi, S.; Garg, A.; Verma, A. Nano lipid based carriers for lymphatic voyage of anti-cancer drugs: An insight into the in-vitro, ex-vivo, in-situ and in-vivo study models. J. Drug Deliv. Sci. Technol., 2020, 59, 101899. doi: 10.1016/j.jddst.2020.101899
  137. Chaturvedi, S.; Garg, A. An insight of techniques for the assessment of permeation flux across the skin for optimization of topical and transdermal drug delivery systems. J. Drug Deliv. Sci. Technol., 2021, 62, 102355. doi: 10.1016/j.jddst.2021.102355
  138. Grabarek, B.O.; Dąbala, M.; Kasela, T.; Gralewski, M.; Gładysz, D. Changes in the expression pattern of DUSP1-7 and miRNA regulating their expression in the keratinocytes treated with LPS and adalimumab. Curr. Pharm. Biotechnol., 2022, 23(6), 873-881. doi: 10.2174/1389201022666210802102508 PMID: 34342258

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024